Merck & Co to buy immunology specialist Prometheus

By Phillip Broadwith2023-04-20T10:36:00

Source: © Sandy Huffaker/Bloomberg/Getty Images

$10.8 billion cash deal give Merck rights to late-stage candidate for two inflammatory bowel conditions

Merck & Co has agreed to buy Prometheus Biosciences, which specialises in developing treatments for immune-modulated diseases, for $10.8 billion (£8.7 billion) in cash.